Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Leveren van tAN om HMB te verminderen: De LUNA-studie (LUNA)

15 oktober 2026 bijgewerkt door: Spark Biomedical, Inc.

Het toedienen van transcutane auriculaire neurostimulatie om hevig menstrueel bloedverlies te verminderen: De LUNA-studie

The LUNA study is a prospective, randomized, double-blind, sham-controlled, decentralized clinical trial in participants with heavy menstrual bleeding of no known structural cause. The study includes two age-based cohorts: adolescents aged 14-21 and adults aged 22-45. Participants in both cohorts will be randomized to receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN), or sham stimulation. Participants will be enrolled into the study over the course of five menstrual cycles. All study activities will occur remotely and in addition to participants' typical treatment for HMB (as allowed by the eligibility criteria).

During the first two consecutive menstrual cycles (M1 - M2, "Baseline Phase"), no tAN treatment will be delivered. Participants will estimate blood loss using the Pictorial Bleeding Assessment Chart (PBAC), and menstrual cramp pain will be assessed with a Numerical Rating Scale (NRS), daily throughout the duration of the menstruation phase of their two baseline menstrual cycles. Menstrual symptoms will be assessed using the Cox Menstrual Symptom Scale (CMSS) and a general quality of life assessment will be conducted on the final day of menstruation using the RAND Short-Form 36 (RAND-36). Menstrual-related quality of life assessments will also be conducted on the final day of each menstruation using the Menstrual Bleeding Questionnaire (MBQ) in the adult cohort, and the adolescent version (aMBQ) in the adolescent cohort.

During the following three menstruations (M3 - M5, "Treatment Phase"), participants will self-administer one 2-hour sham or active tAN session daily, beginning Day 1 of menstruation through the final day of menstruation in each menstrual cycle. Blood loss (via the PBAC) and menstrual cramp pain (via the NRS) will be assessed daily throughout the duration of each menstruation. Quality of life will be assessed with the CMSS, RAND-36, and the MBQ (adults) or aMBQ (adolescents) on the final day of each menstruation. A device usability survey will be completed at the end of M3 and M5. Participants will exit the study after the final day of M5.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

80

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Verenigde Staten
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02111
        • Werving
        • Lindus Health - DECENTRALIZED STUDY
        • Hoofdonderzoeker:
          • Alta DeRoo, MD, MBA
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

14 jaar tot 45 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  1. Regularly menstruating female aged 14-45 years at time of screening
  2. History of menorrhagia as assessed by the Menorrhagia Screening Tool
  3. Stable/consistent use of current non-hormonal medications and supplements for the past three months, willingness to continue use for duration of study, and not start any new medications or homeopathic remedies
  4. Reliable access to an internet-enabled device to complete required questionnaires that is compatible with the study application (iOS 18 and Android 15 or greater)
  5. Willingness to consistently use only study-provided menstrual products throughout duration of the study
  6. Participant PBAC scores are ≥150 for both baseline menstruation months

Exclusion Criteria:

  1. Pregnancy within three months of enrollment
  2. Lactating at the time of enrollment
  3. Typical length of menstruation greater than 14 days
  4. Antifibrinolytic (i.e. tranexamic acid; Lysteda) use within 14 days of enrollment
  5. Known acquired bleeding disorder
  6. Known severe bleeding disorder (participants with mild von Willebrand disease will be eligible to participate in the study)
  7. Use of anticoagulants (i.e. Warfarin, Coumadin, etc.) including platelet inhibitors for 14 days prior to enrollment
  8. Use of prescriptive pain medications and/or use of the following analgesics: Aspirin, naproxen (Aleve), or magnesium salicylate (Doan's) during the study
  9. Use of the copper intrauterine device within the past three months
  10. Structural cause of heavy menstrual bleeding (e.g. fibroids, polyps, etc.) in medical records
  11. Documented thrombocytopenia within the last 12 months (platelet count ≤100,000 per microliter of blood) in medical records
  12. Any use of continuous hormone therapies (e.g., IUD, etc.) within three months prior to enrollment
  13. Use of hormone therapies that have not followed a standard 21/7 dosing regimen for at least six months prior to enrollment
  14. Participant has a history of chronic tobacco use or has ingested nicotine via smoking, vaping, smokeless tobacco, or nicotine patches in the past three months
  15. Participant has a history of epileptic seizures within the past 12 months
  16. Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.)
  17. Participant has a history traumatic brain injury within the past 12 months
  18. Participant has had a splenectomy
  19. Participant has presence of devices (e.g., pacemakers, cochlear prostheses, neurostimulators) and/or uses other neurostimulators
  20. Participant has abnormal ear anatomy or ear infection present
  21. Participant has previously used auricular neurostimulation for any clinical indication
  22. Participant is currently or plans to be enrolled in another clinical trial during enrollment
  23. Participant is a ward of the state
  24. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Active tAN

In the Treatment Phase (M3-M5), participants will self-administer one two-hour session of active transcutaneous auricular neurostimulation (tAN) each day of menstruation.
Apparaat: Sparrow Link

The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle.

Andere namen:
  • Transcutane auriculaire neurostimulatie
Sham-vergelijker: Sham tAN

In the Treatment Phase (M3-M5), participants will self-administer one two-hour session of sham transcutaneous auricular neurostimulation (tAN) each day of menstruation. Participants in the sham group will apply the earpiece and connect the cable to the Patient Controller. The device will be turned on, and appears to function identically to an active device, but will not deliver stimulation through the earpiece.
Apparaat: Sparrow Link (Sham)

Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. The sham device has an identical appearance to the active device.

Andere namen:
  • Transcutane Auriculaire Neurostimulatie (Sham)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pictorial Bleeding Assessment Chart (PBAC)
Tijdsspanne: Daily throughout all five menstruations (up to 5 complete menstrual cycles - estimated 150 days)

The PBAC is a widely accepted tool for patients with HMB to account for menstrual blood loss. Menstrual blood loss is estimated through a selection of images of tampons, pads, clots, and flooding events. Users mark a tally next to the images that best match each the saturation level of the menstruation products they used that day. PBAC data will be recorded by the participants for each calendar day (00:00-23:59 local time). Day 1 is the calendar date on which a menstrual product is first used. This trial will utilize a modified version of the Higham PBAC, where a tally system will be added to each of the images.
Daily throughout all five menstruations (up to 5 complete menstrual cycles - estimated 150 days)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cox Menstrual Symptom Severity Scale (CMSS)
Tijdsspanne: Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)

The CMSS measures menstrual distress and dysmenorrhea. The CMSS Severity subscale is an 18-item self-reported scale that measures severity of menstrual symptoms, including pain, nausea, emotions, etc. during menstruation. The CMSS will be used in this trial to retrospectively measure the frequency and severity of a participant's menstrual symptoms on the final day of each menstruation.
Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)
Numerical Rating Scale (NRS)
Tijdsspanne: Daily throughout all five menstruations (up to 5 complete menstrual cycles - estimated 150 days)

The NRS measures menstrual pain daily on a scale of 0 to 10, with zero representing no pain and 10 representing the worst pain imaginable. This is a commonly used scale in studies of dysmenorrhea and other gynecological pain conditions. The NRS will be used in this trial to measure the severity of a participant's menstrual pain on each day of each menstruation.
Daily throughout all five menstruations (up to 5 complete menstrual cycles - estimated 150 days)
RAND Short Form-36 (RAND-36)
Tijdsspanne: Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)

The RAND-36 is a 36-item patient-reported questionnaire that assesses general quality of life. This questionnaire includes eight variables: physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, mental health, energy and vitality, pain, and general perception of health. This questionnaire will be completed by the participant at the end of each menstruation.
Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)
Menstrual Bleeding Questionnaire (MBQ)
Tijdsspanne: Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)

The MBQ measures the impact of heavy menstrual bleeding on health-related quality of life in adult women. The MBQ is a 20-item self-reported scale that evaluates the frequency and severity of menstrual symptoms and their effects on physical, social, and emotional functioning, daily activities, and overall well-being. Responses are captured on Likert-type scales, with higher scores indicating greater symptom burden and functional impairment. The MBQ will be used in this trial to measure the severity of the adult cohort's menstrual pain on the final day of each menstruation.
Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)
Adolescent Menstrual Bleeding Questionnaire (aMBQ)
Tijdsspanne: Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)

The aMBQ measures HMB-related quality of life in adolescents. The aMBQ is a 19-item self-reported scale that evaluates symptom burden and its effects on school attendance and performance, extracurricular and social activities, physical functioning, and emotional well-being, using Likert-type responses with higher scores indicating greater impact. The aMBQ will be used in this trial to measure the severity of the adolescent cohort's menstrual pain on the final day of each menstruation.
Final day of each menstruation (up to 5 complete menstrual cycles - estimated 150 days)
Device Usability Questionnaire
Tijdsspanne: Final day of Menstruation 3 and Menstruation 5 (estimated 10 days per menstruation)

The Device Usability Questionnaire is a 16-item survey that includes both Likert-scale questions (ranging from Strongly Agree to Strongly Disagree) and open-ended free-text responses. It is designed to assess participants' overall satisfaction with the device and to evaluate how easily they were able to operate it using the provided instructions and support materials (Instruction for Use and Quick Start Guide).
Final day of Menstruation 3 and Menstruation 5 (estimated 10 days per menstruation)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Spark Biomedical, Inc.

Medewerkers

Yale University
Oregon Health and Science University
Lindus Health
Wellcome Leap
University of Michigan Health

Onderzoekers

  • Hoofdonderzoeker: Navid Khodaparast, PhD, Spark Biomedical, Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 maart 2026

Primaire voltooiing (Geschat)

31 augustus 2027

Studie voltooiing (Geschat)

31 augustus 2027

Studieregistratiedata

Eerst ingediend

6 januari 2026

Eerst ingediend dat voldeed aan de QC-criteria

7 januari 2026

Eerst geplaatst (Werkelijk)

8 januari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

15 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 5L-BLD-06

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren